Cargando…

An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy

BACKGROUND: Historically, the molecular classification of colorectal cancer (CRC) was based on the global genomic status, which identified microsatellite instability in mismatch repair (MMR) deficient CRC, and chromosomal instability in MMR proficient CRC. With the introduction of immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sibilio, Pasquale, Belardinilli, Francesca, Licursi, Valerio, Paci, Paola, Giannini, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082922/ https://www.ncbi.nlm.nih.gov/pubmed/35534873 http://dx.doi.org/10.1186/s13062-022-00324-y

Ejemplares similares

In silico recognition of a prognostic signature in basal-like breast cancer patients
por: Conte, Federica, et al.
Publicado: (2022)

Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer
por: Belardinilli, Francesca, et al.
Publicado: (2020)

In silico drug repurposing in COVID-19: A network-based analysis
por: Sibilio, Pasquale, et al.
Publicado: (2021)

MIENTURNET: an interactive web tool for microRNA-target enrichment and network-based analysis
por: Licursi, Valerio, et al.
Publicado: (2019)

Identification of Potential Repurposable Drugs in Alzheimer’s Disease Exploiting a Bioinformatics Analysis
por: Fiscon, Giulia, et al.
Publicado: (2022)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
por: Haslam, Alyson, et al.
Publicado: (2019)

Publisher Correction: Computational identification of specific genes for glioblastoma stem-like cells identity
por: Fiscon, Giulia, et al.
Publicado: (2018)

Computational identification of specific genes for glioblastoma stem-like cells identity
por: Fiscon, Giulia, et al.
Publicado: (2018)

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Psychiatric Disorders and Oxidative Injury: Antioxidant Effects of Zolpidem Therapy disclosed In Silico
por: Bortoli, Marco, et al.
Publicado: (2019)

Immune checkpoints and immunotherapy for colorectal cancer
por: Singh, Preet Paul, et al.
Publicado: (2015)

To disclose, or not to disclose? Context matters
por: Rahimzadeh, Vasiliki, et al.
Publicado: (2015)

Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world
por: Ciprandi, Giorgio, et al.
Publicado: (2017)

Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer
por: Sasidharan Nair, Varun, et al.
Publicado: (2020)

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
por: Machiraju, Devayani, et al.
Publicado: (2021)

Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92‐Gene Assay
por: Raghav, Kanwal, et al.
Publicado: (2020)

Analysis of Mononuclear Phagocytes Disclosed the Establishment Processes of Two Macrophage Subsets in the Adult Murine Kidney
por: Zhu, Qian, et al.
Publicado: (2022)

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
por: Bobin, Arthur, et al.
Publicado: (2020)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Cancer Immunotherapy: The Checkpoint between Chronic Colitis and Colorectal Cancer
por: Ephraim, Ramya, et al.
Publicado: (2022)

JARID1B expression and its function in DNA damage repair are tightly regulated by miRNAs in breast cancer
por: Mocavini, Ivano, et al.
Publicado: (2019)

Cyclooxygenase-2 Inhibitor Parecoxib Was Disclosed as a PPAR-γ Agonist by In Silico and In Vitro Assay
por: Xiao, Bin, et al.
Publicado: (2021)

Immune Checkpoints in Circulating and Tumor-Infiltrating CD4(+) T Cell Subsets in Colorectal Cancer Patients
por: Toor, Salman M., et al.
Publicado: (2019)

Why do children and adolescents with epilepsy disclose or not disclose their condition to their friends?
por: Jeschke, Sarah, et al.
Publicado: (2020)

Predictive Response to Immunotherapy Score: A Useful Tool for Identifying Eligible Patients for Allergen Immunotherapy
por: Mormile, Ilaria, et al.
Publicado: (2022)

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
por: Duan, Xiaopin, et al.
Publicado: (2019)

RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study
por: Nicolazzo, Chiara, et al.
Publicado: (2022)

Spherical Oligo-Silicic Acid SOSA Disclosed as Possible Endogenous Digitalis-Like Factor
por: Kerek, Franz, et al.
Publicado: (2015)

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
por: Capalbo, Carlo, et al.
Publicado: (2014)

Left Atrial trajectory impairment in Hypertrophic Cardiomyopathy disclosed by Geometric Morphometrics and Parallel Transport
por: Piras, Paolo, et al.
Publicado: (2016)

Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer
por: Miura, Yuki, et al.
Publicado: (2021)

Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy
por: Xie, Lu, et al.
Publicado: (2022)

Correlations between Circulating and Tumor-Infiltrating CD4(+) T Cell Subsets with Immune Checkpoints in Colorectal Cancer
por: Al-Mterin, Mohammad A., et al.
Publicado: (2022)

A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer
por: Capalbo, Carlo, et al.
Publicado: (2019)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
por: Haslam, Alyson, et al.
Publicado: (2020)

The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma
por: Ozaki, Kai, et al.
Publicado: (2021)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Tumors of the Brain Disclosed by Autopsy
por: Gill, H. D.
Publicado: (1895)

“I” Am Willing to Disclose, but “We” are Unwilling: The Impact of Self-Construal on Individuals’ Willingness to Disclose
por: Zhang, Changqing, et al.
Publicado: (2021)

Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
por: Hsiehchen, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gu4a5574ehr1bdculj890b4v5q